Loading...
VEA Impex (I) Private Limited — Cetuximab Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #7 for Cetuximab · $22.5K export value · DGFT Verified
VEA Impex (I) Private Limited is the #7 Indian exporter of Cetuximab with $22.5K in export value and 4 verified shipments. VEA Impex (I) Private Limited holds a 1.6% market share in Cetuximab exports across 2 countries. The company exports 14 pharmaceutical products worth $229.9K across 3 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| TURKEY | $210.1K | 5 | 29.4% |
| UNITED KINGDOM | $131.1K | 4 | 18.3% |
| SAINT KITTS AND NEVIS | $50.3K | 9 | 7.0% |
| NICARAGUA | $50.0K | 1 | 7.0% |
| BRAZIL | $46.1K | 12 | 6.5% |
| CAYMAN ISLANDS | $38.9K | 9 | 5.4% |
| MALDIVES | $34.5K | 6 | 4.8% |
| KENYA | $33.6K | 22 | 4.7% |
| UNITED STATES | $24.4K | 5 | 3.4% |
| JORDAN | $20.6K | 1 | 2.9% |
India exports Cetuximab to 30 countries. The top destination is TURKEY (29.4%), followed by UNITED KINGDOM and SAINT KITTS AND NEVIS.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| AS PER INVOICE TURKEY | TURKEY | $90.4K | 2 |
| JOSE RONALDO DE DEUS | BRAZIL | $38.8K | 10 |
| INDIRA GANDHI MEMORIAL HOSPITAL | MALDIVES | $34.5K | 6 |
| THE PURCHASE MANAGE R HEALTH CITY CAYMAN ISLAND LIMITED | UNITED KINGDOM | $11.2K | 2 |
| PHARMACIE ARC EN CIEL COCODY | COTE D IVOIRE | $10.8K | 2 |
India's Cetuximab is purchased by 51 buyers worldwide. The top buyer is AS PER INVOICE TURKEY (TURKEY), followed by JOSE RONALDO DE DEUS and INDIRA GANDHI MEMORIAL HOSPITAL.
India exported $294.3K worth of Cetuximab through 115 shipments from 43 suppliers to 30 countries, serving 51 buyers globally. VEA Impex (I) Private Limited contributes $22.5K to this total, accounting for 1.6% of India's Cetuximab exports.
VEA Impex (I) Private Limited's average Cetuximab shipment value is $5.6K per consignment, based on 4 shipments totaling $22.5K.
VEA Impex (I) Private Limited ranks #7 among 43 Indian Cetuximab exporters with a 1.6% market share. The top 3 exporters are VAMA LIFECARE PRIVATE LIMITED ($95.8K), MILES INTERNATIONAL ($51.5K), MATSUN EXPORTS ($38.8K). VEA Impex (I) Private Limited processed 4 shipments to 2 destination countries.
What VEA Impex (I) Private Limited must comply with to export Cetuximab to its top destination countries
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | NU HOSPITALS PRIVATE LIMITED | $34.5K | 6 | 1 | $5.8K |
| 6 | BRINTON PHARMACEUTICALS LIMITED | $13.3K | 5 | 1 | $2.7K |
| 7 | VEA IMPEX I PRIVATE LIMITED ★ | $13.0K | 4 | 2 | $3.3K |
| 8 | VEA IMPEX (I) PRIVATE LIMITED ★ | $9.5K | 3 | 2 | $3.2K |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 39 | 33.9% |
| SAHAR AIR CARGO ACC (INBOM4) | 29 | 25.2% |
| Bombay Air Cargo | 12 | 10.4% |
| BANGALORE ACC (INBLR4) | 9 | 7.8% |
| Bombay Air | 9 | 7.8% |
| CHENNAI AIR | 3 | 2.6% |
| BANGALORE AIR | 2 | 1.7% |
| LCS Nepalgunj Road (INNGRB ) | 2 | 1.7% |
VEA Impex (I) Private Limited also exports these advanced oncology products. Each links to the detailed product page.
VEA Impex (I) Private Limited exports 14 products worth $229.9K. Beyond Cetuximab, top products include Darunavir, Daratumumab, Nivolumab, Vinorelbine, Brufen. View the complete VEA Impex (I) Private Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Cetuximab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for VEA Impex (I) Private Limited's Cetuximab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
VEA Impex (I) Private Limited
Full Company Profile →
14 products · $229.9K total trade · 3 categories
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
VEA Impex (I) Private Limited ranks #7 among 43 Indian Cetuximab exporters. Average shipment value of $3.3K compared to the market average of $6.8K. The closest competitors by value are NU HOSPITALS PRIVATE LIMITED and BRINTON PHARMACEUTICALS LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 30+ countries, 51+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for VEA Impex (I) Private Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Cetuximab. For current shipment-level data, contact TransData Nexus.